Abstract:Background/Aims: MicroRNAs play regulatory role in cardiovascular disease. MicroRNA-223 (miR-223) was found to be expressed abundantly in myocardium. TNNI3K, a novel cardiac troponin I (cTnI)-interacting and cardiac hypertrophy related kinase, is computationally predicted as a potential target of miR-223. This study was designed to investigate the cellular and molecular effects of miR-223 on cardiomyoctye hypertrophy, focusing on the role of TNNI3K. Methods: Neonatal rat cardiomyocytes (CMs) were cultured, and CMs hypertrophy was induced by endothelin-1 (ET-1). in vivo cardiac hypertrophy was induced by transverse aorta constriction (TAC) in rats. Expression of miR-223 in CMs and myocardium was detected by real-time PCR (RT-PCR). MiR-223 and TNNI3K were overexpressed in CMs via chemically modified sense RNA (miR-223 mimic) transfection or recombinant adenovirus infection, respectively. Cell size was measured by surface area calculation using fluorescence microscopy after anti-a-actinin staining. Expression of hypertrophy-related genes was detected by RT-PCR. The protein expression of TNNI3K and cTnI was determined by Western blots. Luciferase assay was employed to confirm the direct binding of miR-223 to the 3'UTR of TNNI3K mRNA. Intracellular calcium was measured by sensitive fluorescent indicator (Furo-2). Video-based edge detection system was employed to measure cardiomyocyte contractility. Results: MiR-223 was downregulated in ET-1 induced hypertrophic CMs and in hypertrophic myocardium compared with respective controls. MiR-223 overexpression in CMs alleviated ET-1 induced hypertrophy, evidenced by smaller cell surface area and downregulated ANP, alpha-actinin, Myh6 and Myh7 expression. Luciferase reporter gene assay showed that TNNI3K serves as a direct target gene of miR-223. In miR-223-overexpressed CMs, the protein expression of TNNI3K was significantly downregulated. MiR-223 overexpression also rescued the upregulated TNNI3K expression in hypertrophic CMs. Furthermore, cTnI phosphorylation was downregulated post miR-223 overexpression. Ad.rTNNI3K increased intracellular Ca2+ concentrations and cell shortening in CMs, while miR-223 overexpression significantly rescued these hypertrophic effects. Conclusion: By direct targeting TNNI3K, miR-223 could suppress CMs hypertrophy via downregulating cTnI phosphorylation, reducing intracellular Ca2+ and contractility of CMs. miR-223/TNNI3K axis may thus be major players of CMs hypertrophy. Copyright (C) 2015 S. Karger AG, Basel

Tnni3k, A Cardiac-Specific Kinase, Promotes Physiological Cardiac Hypertrophy In Transgenic Mice

Overexpression of TNNI3K, a Cardiac-Specific MAP Kinase, Promotes P19CL6-derived Cardiac Myogenesis and Prevents Myocardial Infarction-Induced Injury.

TNNI3K is a Novel Mediator of Myofilament Function and Phosphorylates Cardiac Troponin I

Adenovirus-Mediated Overexpression of Cardiac Troponin I-Interacting Kinase Promotes Cardiomyocyte Hypertrophy

Inhibition of TRPC1 Prevents Cardiac Hypertrophy Via NF-κB Signaling Pathway in Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Overexpression of Cardiac-Specific Kinase TNNI3K Promotes Mouse Embryonic Stem Cells Differentiation into Cardiomyocytes

Abstract 137: The Role of TNNI3K in Adult Mammalian Heart Regeneration

Tumor Necrosis Factor Receptor-Associated Factor 3 is A Positive Regulator of Pathological Cardiac Hypertrophy

MicroRNA-223 displays a protective role against cardiomyocyte hypertrophy by targeting cardiac troponin I-interacting kinase.

Type III Transforming Growth Factor-β Receptor Drives Cardiac Hypertrophy Through Β-Arrestin2–dependent Activation of Calmodulin-Dependent Protein Kinase II

Cloning and Characterization of a Novel Cardiac-Specific Kinase That Interacts Specifically with Cardiac Troponin I

GCN5-mediated regulation of pathological cardiac hypertrophy via activation of the TAK1-JNK/p38 signaling pathway

C1q-tumour Necrosis Factor-Related Protein-3 Exacerbates Cardiac Hypertrophy in Mice.

Hint1 (Histidine Triad Nucleotide-Binding Protein 1) Attenuates Cardiac Hypertrophy Via Suppressing Hoxa5 (Homeobox A5) Expression

TNIP3 protects against pathological cardiac hypertrophy by stabilizing STAT1

Dickkopf-3 attenuates pressure overload-induced cardiac remodelling.

TAK1 is Activated in the Myocardium after Pressure Overload and is Sufficient to Provoke Heart Failure in Transgenic Mice.

Protein Kinase D3 is a Pivotal Activator of Pathological Cardiac Hypertrophy by Selectively Increasing the Expression of Hypertrophic Transcription Factors

Abstract 026: Role of Tank in the Regulation of Pathological Cardiac Hypertrophy

The TNNI3 P.r186q Mutation is Responsible for Hypertrophic Cardiomyopathy Via Promoting FASN-stimulated Abnormal Fatty Acid Metabolism

Casein Kinase-2 Interacting Protein-1 Regulates Physiological Cardiac Hypertrophy via Inhibition of Histone Deacetylase 4 Phosphorylation